|
[1] LOOMBA R, SANYAL AJ. The global NAFLD epidemic[J]. Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :686-690.
|
|
[2] ZHU CY, ZHOU D, FAN JG. Advances in diagnosis and treatment of nonalcoholic fatty liver disease[J]. Chin J Hepatol, 2016, 24 (2) :81-84. (in Chinese) 朱婵艳, 周达, 范建高.非酒精性脂肪性肝病的诊断与治疗进展[J].中华肝脏病杂志, 2016, 24 (2) :81-84.
|
|
[3] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol, 2018, 34 (5) :947-957. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南 (2018年更新版) [J].临床肝胆病杂志, 2018, 34 (5) :947-957.
|
|
[4] TILG H, CANI PD, MAYER EA. Gut microbiome and liver diseases[J]. Gut, 2016, 65 (12) :2035-2044.
|
|
[5] VILAR-GOMEZ E, MARTINEZ-PEREZ Y, CALZADILLABERTOT L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J]. Gastroenterology, 2015, 149 (2) :367-378.
|
|
[6] RATZIU V, HARRISON SA, FRANCQUE S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-αand-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology, 2016, 150 (5) :1147-1159.
|
|
[7] BELFORT R, HARRISON SA, BROWN K, et al. A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis[J]. N Engl J Med, 2006, 355 (22) :2297-2307.
|
|
[8] AITHAL GP, THOMAS JA, KAYE PV, et al. Randomized, placebo controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis[J]. Gastroenterology, 2008, 135 (4) :1176-1184.
|
|
[9] DEPAOLI AM, HIGGINS LS, HENRY RR, et al. Can a selective PPARγmodulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?[J]. Diabetes Care, 2014, 37 (7) :1918-1923.
|
|
[10] JAIN MR, GIRI SR, TRIVEDI C, et al. Saroglitazar, a novel PPARα/γagonist with predominant PPARαactivity, shows lipid lowering and insulin-sensitizing effects in preclinical models[J].Pharmacol Res Perspect, 2015, 3 (3) :e00136.
|
|
[11] JANI RH, PAI V, JHA P, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI) [J]. Diabetes Technol Ther, 2014, 16 (2) :63-71.
|
|
[12] MARKHAM A, KEAM SJ. Obeticholic acid:First global approval[J]. Drugs, 2016, 76 (12) :1221-1226.
|
|
[13] NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT) :A multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385 (9972) :956-965.
|
|
[14] RATZIU V, de LEDINGHEN V, OBERTI F, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis[J]. J Hepatol, 2011, 54 (5) :1011-1019.
|
|
[15] VATNER DF, WEISMANN D, BEDDOW SA, et al. Thyroid hormone receptor-βagonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways[J]. Am J Physiol Endocrinol Metab, 2013, 305 (1) :e89-e100.
|
|
[16] SAFADI R, KONIKOFF FM, MAHAMID M, et al. The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2014, 12 (12) :2085-2091.
|
|
[17] MUSSO G, CASSADER M, GAMBINO R. Cholesterol lowering therapy for the treatment of nonalcoholic fatty liver disease:An update[J].Curr Opin Lipidol, 2011, 22 (6) :489-496.
|
|
[18] GILEAD SCIENCES, INC. Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver CongressTM 2017 Gilead[R/OL].[2017-04-21]. https://www. gilead. com/news/press-releases/2017/4/gilead-presents-proofofconcept-data-for-gs0976-in-nonalcoholic-steatohepatitis-nash-at-the-international-livercongress-2017
|
|
[19] ARMSTRONG MJ, GAUNT P, AITHAL GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN) :A multicentre, double-blind, randomised, placebocontrolled phase 2 study[J]. Lancet, 2016, 387 (10019) :679-690.
|
|
[20] CUI J, PHILO L, NGUYEN P, et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease:A randomized controlled trial[J]. J Hepatol, 2016, 65 (2) :369-376.
|
|
[21] JOY TR, MCKENZIE CA, TIRONA RG, et al. Sitagliptin in patients with non-alcoholic steatohepatitis:A randomized, placebocontrolled trial[J]. World J Gastroenterol, 2017, 23 (1) :141-150.
|
|
[22] BUGIANESI E, GENTILCORE E, MANINI R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease[J]. Am J Gastroenterol, 2005, 100 (5) :1082-1090.
|
|
[23] UYGUN A, KADAYIFCI A, ISIK AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2004, 19 (5) :537-544.
|
|
[24] SEKO Y, SUMIDA Y, TANAKA S, et al. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus[J]. Hepatol Res, 2017, 47 (10) :1072-1078.
|
|
[25] KOMIYA C, TSUCHIYA K, SHIBA K, et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type2 diabetic patients irrespective of body weight reduction[J]. PLo S One, 2016, 11 (3) :e0151511.
|
|
[26] TAKASE T, NAKAMURA A, MIYOSHI H, et al. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin:An association with glucose-lowering effects[J]. Endocr J, 2017, 64 (3) :363-367.
|
|
[27] SANYAL AJ, CHALASANI N, KOWDLEY KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 362 (18) :1675-1685.
|
|
[28] POCKROS PJ, SCHIFF ER, SHIFFMAN ML, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C[J]. Hepatology, 2007, 46 (2) :324-329.
|
|
[29] BARREYRO FJ, HOLOD S, FINOCCHIETTO PV, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis[J].Liver Int, 2015, 35 (3) :953-966.
|
|
[30] ZEIN CO, YERIAN LM, GOGATE P, et al. Pentoxifylline improves nonalcoholic steatohepatitis:A randomized placebo-controlled trial[J]. Hepatology, 2011, 54 (5) :1610-1619.
|
|
[31] SHIRAKAMI Y, SHIMIZU M, KUBOTA M, et al. Pentoxifylline prevents nonalcoholic steatohepatitis-related liver pre-neoplasms by inhibiting hepatic inflammation and lipogenesis[J]. Eur J Cancer Prev, 2016, 25 (3) :206-215.
|
|
[32] CAO Y, SHEN F, XU LM, et al. Assoclation of gut microbiota with endotoxemia and nonalcoholic fatty liver disease[J]. J Pract Hepatol, 2012, 15 (2) :163-165. (in Chinese) 曹毅, 沈峰, 徐雷鸣, 等.肠道菌群和内毒素血症与非酒精性脂肪性肝病[J].实用肝脏病杂志, 2012, 15 (2) :163-165.
|
DownLoad: